•  04/2017 DHI awarded a 3-year term of accreditation by the American College of Radiology (“ACR”) for Oncology, Brain (PET Services). The ACR gold seal of accreditation represents the highest level of image quality and patient safety. It is awarded only to facilities meeting ACR Practice Parameters and Technical Standards after a peer-review evaluation by board-certified physicians and medical physicists who are experts in the field. Image quality, personnel qualifications, adequacy of facility equipment, quality control procedures and quality assurance programs are assessed. 
  • 03/2017 – DHI begins performing PET/CT imaging with Axumin™ (fluciclovine F 18) injection which is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. 
  • 03/2017 – DHI launches the Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study. The 3 isotopes approved for the study are Neuraceq, Amyvid, and Vizamyl. The IDEAS Study will focus on brain images called amyloid PET scans which can show if amyloid plaques are building up in the brain. The presence or absence of amyloid plaques will help doctor’s determine the likelihood that patient’s symptoms are caused by Alzheimer’s disease. 
  • 07/2016 – Molecular Imaging Technologies, LLC (“MIT”) acquires Decatur Health Imaging, LLC(“DHI”), also known as OMI Management of Decatur, LLC (“OMI”), an independent outpatient diagnostic testing facility providing outpatient PET/CT imaging scans.  DHI will continue to provide outstanding PET/CT imaging to its physicians, patients, and the community and there will be no disruption to day to day operations.  DHI offers excellent PET/CT imaging, scheduling, pre-certification and billing, physician/patient education, certified clinical staff, and quality programs to enhance physician/patient satisfaction. 
  • 09/2012 – DHI begins to offer Amyvid® for PET/CT imaging of the brain to identify the presence of plaque in the brain, which has been shown to be a precursor to Alzheimer’s Disease (AD) and other causes of cognitive decline. 
  • 2011 – DHI begins participation in the NOPR for Sodium Fluoride (NaF-18) which is a highly sensitive bone seeking PET tracer used for detection of skeletal abnormalities. The uptake mechanism is similar to Tc-99m MDP, but with better physical characteristics for imaging.